Skip to main content

Peer Review reports

From: Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Original Submission
14 Sep 2021 Submitted Original manuscript
29 Oct 2021 Reviewed Reviewer Report
8 Nov 2021 Reviewed Reviewer Report
3 Dec 2021 Author responded Author comments - James C.H. Yang
Resubmission - Version 2
3 Dec 2021 Submitted Manuscript version 2
6 Jan 2022 Reviewed Reviewer Report
4 Feb 2022 Reviewed Reviewer Report
16 Feb 2022 Author responded Author comments - James C.H. Yang
Resubmission - Version 3
16 Feb 2022 Submitted Manuscript version 3
27 Feb 2022 Reviewed Reviewer Report
14 Apr 2022 Author responded Author comments - James C.H. Yang
Resubmission - Version 4
14 Apr 2022 Submitted Manuscript version 4
16 May 2022 Author responded Author comments - James C.H. Yang
Resubmission - Version 5
16 May 2022 Submitted Manuscript version 5
Publishing
23 May 2022 Editorially accepted
7 Jun 2022 Article published 10.1186/s12885-022-09687-x

You can find further information about peer review here.

Back to article page